Improving absorption of cobinamide to treat Marfan Syndrome
Official title: Cobinamide as a disease-modifying treatment for Marfan Syndrome: optimizaation of absorption
Funded at University of California, San Diego · NIH-11135834 · Data updated 2026-11-12
This study is looking at how a special antioxidant called cobinamide might help people with Marfan Syndrome by improving how well their bodies absorb it, with the hope of reducing serious heart problems in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | June 1, 2025 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $405,781 |
| NIH project number | 1R61HL175687-01A1 |
| Project ID | NIH-11135834 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Marfan Syndrome, particularly those at risk for aortic aneurysms.
✕Less likely to help
Patients without Marfan Syndrome or those who do not have a significant risk of aortic complications may not benefit from this research.
What this research studies
This research focuses on Marfan Syndrome, a genetic disorder that can lead to life-threatening aortic aneurysms. The study investigates cobinamide, a powerful antioxidant, as a potential disease-modifying treatment. Researchers aim to enhance the absorption of cobinamide in the body to ensure effective long-term therapy. By optimizing how the drug is absorbed, the goal is to reduce oxidative stress and prevent serious complications associated with the condition.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option that modifies the disease progression of Marfan Syndrome.
How similar studies have gone: Previous research has shown promise in using cobinamide for similar conditions, indicating potential for success in this novel application.
Where this research is happening
-
University of California, San Diego
La Jolla, United States Active
Researchers
- Principal investigator: Boss, Gerry R — University of California, San Diego
- Study coordinator: Boss, Gerry R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.